Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13060800 | 1.00 | TAS1R3 (0.41) | TAS1R3TAS1R1ROCK2ROCK1UTS2R | |
| SCHEMBL13005536 | 0.92 | ROCK2 (0.40) | TAS1R3TAS1R1ROCK2ROCK1UTS2R | |
| SCHEMBL13005534 | 0.92 | ROCK2 (0.40) | TAS1R3TAS1R1ROCK2ROCK1UTS2R | |
| SCHEMBL13060890 | 0.86 | CTSL (0.41) | TAS1R3TAS1R1ROCK2ROCK1UTS2R | |
| SCHEMBL13060892 | 0.86 | CTSL (0.41) | TAS1R3TAS1R1ROCK2ROCK1UTS2R | |
| SCHEMBL13061023 | 0.84 | ROCK2 (0.51) | ROCK2ROCK1UTS2R | |
| SCHEMBL13060640 | 0.83 | TAS1R3 (0.40) | TAS1R3TAS1R1ROCK2ROCK1UTS2R | |
| SCHEMBL13060643 | 0.82 | ROCK2 (0.44) | ROCK2ROCK1HDAC4 | |
| SCHEMBL13061226 | 0.82 | ROCK2 (0.44) | ROCK2ROCK1HDAC4 | |
| SCHEMBL13060641 | 0.81 | MEN1 (0.41) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851637-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |